For most of psychiatric medicine’s history, the treatment of depression operated on a single timeline: patients started a medication, waited four to six weeks to assess the response, adjusted or switched if the response was inadequate, and repeated the cycle. This timeline was accepted as a feature of how antidepressants work rather than a problem to be solved. The development of Spravato changed that assumption in a fundamental way.
Spravato, the brand name for esketamine nasal spray, was approved by the FDA in 2019 for treatment-resistant depression and has since become one of the most clinically significant advances in psychiatric pharmacology in a generation. Understanding what it is, how it works, and who it is designed to help is increasingly relevant for patients who have not achieved adequate relief through conventional antidepressant treatment.
What Spravato Actually Is
Spravato is a nasal spray formulation of esketamine, which is the S-enantiomer of the anaesthetic drug ketamine. The S-enantiomer was selected for development because it binds more potently to the NMDA receptor, the primary target through which ketamine-based treatments produce their antidepressant effects, and requires lower doses to achieve the same pharmacological effect as racemic ketamine.
The delivery route, intranasal self-administration under healthcare supervision, was chosen to enable outpatient use while maintaining the clinical oversight that the treatment requires. Patients administer the spray themselves in a certified healthcare facility, under direct observation, and remain monitored for at least two hours after each dose before being cleared to leave.
This model differs from intravenous ketamine infusion, which delivers the drug directly into the bloodstream through a drip. The pharmacokinetics are different, the subjective experience during treatment may differ, and the regulatory framework surrounding each is distinct. Spravato is FDA-approved specifically for depression; IV ketamine is used off-label. Both produce antidepressant effects through the glutamate system, but they are not interchangeable treatments.
According to the
National Institute of Mental Health, novel treatments that target the glutamate system represent one of the most important advances in depression pharmacology in decades, offering a genuinely different mechanism of action for patients who have not responded to traditional antidepressants.
Who Spravato Is Approved For
Spravato has two approved indications. The first is treatment-resistant depression in adults, defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications taken at appropriate doses for appropriate durations. The second, approved in 2020, is major depressive disorder with acute suicidal ideation or behaviour, where the rapid onset of effect is particularly clinically valuable.
These two indications reflect different clinical contexts. The treatment-resistant indication is appropriate for patients whose depression has been a persistent challenge despite genuine attempts at conventional pharmacological treatment. The suicidal ideation indication reflects the unique clinical value of a treatment that can produce meaningful improvements in mood within hours rather than weeks, a timeline that is genuinely significant in acute crisis situations.
Patients with certain medical conditions may not be appropriate candidates for Spravato. These include those with uncontrolled hypertension or unstable cardiovascular disease, those with a history of intracerebral haemorrhage, those with current or past psychotic disorder, and those with certain other conditions specified in the prescribing information. A thorough pre-treatment medical and psychiatric evaluation is essential before Spravato is initiated.
The Treatment Programme in Practice
Village TMS Spravato treatment programmes follow the standard dosing schedule established in the clinical trials. The induction phase involves twice-weekly administration for four weeks. The maintenance phase that follows involves once-weekly dosing for four weeks, then fortnightly dosing for ongoing maintenance as long as continued treatment is clinically appropriate.
Each treatment visit involves the patient self-administering the nasal spray under direct observation, then remaining at the clinic for at least two hours of monitoring. Patients should not drive on the day of treatment and should arrange transport to and from the clinic. The monitoring period is used to observe for dissociative effects, sedation, and haemodynamic changes that are the most commonly reported effects of treatment.
Most patients experience some degree of dissociation during the monitoring period, particularly in the earlier treatment sessions. This resolves as the drug clears the system and does not persist into the following day for most patients. Understanding this in advance helps patients approach the treatment experience with appropriate expectations rather than being alarmed by an effect that is normal and expected.
Finding Spravato Treatment
For patients considering whether Spravato is right for them, the first step is finding a clinic that offers it and meets the Spravato REMS certification requirements that the FDA mandates for all dispensing sites. These requirements exist to ensure that the treatment is administered in a setting with the capacity to monitor patients appropriately and manage any adverse effects that arise.
For patients in New York City searching for
Spravato near me, access is genuinely good. Village TMS is a certified Spravato treatment centre, and their clinical team brings the psychiatric expertise to not only administer the treatment safely but to integrate it appropriately with each patient’s broader care plan.
The decision about whether Spravato is the right option for a given patient is one that requires a full psychiatric evaluation. It is not a treatment that should be initiated without a clear understanding of the patient’s history, their previous treatment trials, their current medications, and the specific clinical objectives the treatment is meant to achieve. Village TMS conducts this evaluation as the foundation of every Spravato programme, ensuring that patients who receive the treatment are genuinely well-suited to it.
A Turning Point for Some Patients
For patients who have spent years cycling through antidepressants without achieving adequate relief, the existence of Spravato represents something genuinely worth knowing about. The speed of action, the distinct mechanism, and the FDA approval for treatment-resistant depression make it a credible option rather than an experimental one, and access to quality Spravato treatment in New York City is real.
Village TMS offers comprehensive evaluations and personalised Spravato treatment programmes for patients who meet the clinical criteria. If you have been living with treatment-resistant depression and want to explore whether Spravato could be part of your recovery, contact Village TMS today to schedule your initial consultation.
